earways medical

1. 2017PARNASA 61 – Biomedical Fund
EarWays Medical

2. ABOUT US
EarWays Medical is offering solutions for earwax removal and management treatments
both for professional ear care givers and home care users.
The patent pending technology of EarWays Medical uses a flexible tip design to facilitate
ear wax collection with minimal risk. It is easy to use, self-explanatory, and disposable.
The product allows the user to safely remove ear wax from the ear in a safe and effective
manner. It was designed in consultation with ear, nose and throat doctors to ensure safety and
minimize risk to the user.
EarWays Pro and EarWays Homecare are available in several spiral head diameters for
adults, children and toddlers.
PARNASA 61 – Biomedical Fund 2017

3. MISSION
To set the new gold standard in earwax management and
removal, by introducing innovative products for professional
ear care givers and homecare users.
2017PARNASA 61 – Biomedical Fund

4.  EarWays Pro - final design stage
 EarWays Homecare - advanced design stage
 National phase (US, EU, CH, JP, IL) submitted
 CE approved
 US trade name
 Over 150 successful cases
 In discussions with Japanese lead player
Signed commitments from Belgian and Israeli distributors
 Recruited Scientific Advisory Board
 In discussion with hearing aids manufacturer, hearing institutions
 Commencing Clinical Study.
2017
HIGHLIGHTS
PARNASA 61 – Biomedical Fund

5. MARKET ANALYSIS
2017PARNASA 61 – Biomedical Fund
USA EarWays
Pro
USA EarWays
Homecare
Europe EarWays
Pro
Europe EarWays
Homecare
$142M
$926M
$389M
$1.667M
Total Addressable Market EU & USA $3B
USA EarWays Pro
USA EarWays Homecare
Europe EarWays Pro
Europe EarWays Homecare
US EUROPE

6. 2017PARNASA 61 – Biomedical Fund
EarWays Pro EarWays Homecare
US TARGET MARKET

7. 10
8
6
4
2
0
2018 2019 2020 2021 2022
FORECASTING
2017
Revenue forecast in US $M
PARNASA 61 – Biomedical Fund

8. $1,700 M
$1,275 M
$850 M
$425 M
$0 M
USA
EarWays Pro
USA EarWays
Homecare
Europe
EarWays Pro
Europe EarWays
Homecare
$3 Billion Total addressable market of Europe
and USA
Entered into partnerships for enhanced distribution
and marketing network
ADDITIONAL INSIGHTS
2017PARNASA 61 – Biomedical Fund

9. Raised to date:
$50K Tnufa - Israeli Office of
Chief Scientist
$100K Self Funding
$100K Angel Investor
$250K Parnasa VC
FUNDINGSEEKING
2017PARNASA 61 – Biomedical Fund
Manufacturing for mass production,
expanded clinical studies, business
development, sales & marketing
$1M
Partnerships; Joint
Ventures; Distribution
Networks
USE OF PROCEEDS

10. Reached
16: EarWays Pro - Finalize design and Clinical Study in Israel
Q1 17:EarWays Pro - Design for Manufacturing and initial sale
Upcoming
Q2 17: EarWays Pro - Limited Market Release EU & US,
EarWays Medical Consumer – Finalize Design for clinical study
Q3 17: EarWays Pro - Launch in EU
EarWays Pro - Limited Market release in the US.
MILESTONES
2017PARNASA 61 – Biomedical Fund

11. THE TEAM
Dr. Kraitzer is an entrepreneur, biomaterials specialist, and
an inventor in the field of medical device.
He has proven record in management and problem solving
skills in both scientific and industrial environments with
extensively experienced engineering capabilities and broad
experience in medical device technology, product
development, manufacturing and commercialization in view
of regulatory requirements (US and European).
2017PARNASA 61 – Biomedical Fund
Dr. Amir Kraitzer
Founder & CTO

12. THE TEAM
2017
Since 2008, Yael has been advising and coaching startups
on their strategy, business development, and fundraising.
She has extensive international experience and expertise
within the startup ecosystem, and holds deep knowledge
of the life science industry.
She managed marketing for a US based startup, giving
her the experience needed to head up the Startup Center
at the Israeli Export Institute and create a technology
matchmaking position at Ernst & Young Israel.
PARNASA 61 – Biomedical Fund
Yael Karlin
Managing Director

13. Offers safe and
effective solution
for home care
users
Has
successfully
covered over
150 cases
Provides high
efficiency even in
hard and complex
cases
Single use device
offering maximal
protection of ear
hygiene
2017
ADVANTAGES
PARNASA 61 – Biomedical Fund

14. Tnufa Israeli Self Funding Angel Investor Parnasa (VC)
$250 K
$200 K
$150 K
$100 K
$50 K
$0 K
Fundingsources
Uses of Proceeds
Manufacturing for mass production
Expanded clinical studies, business development, sales and marketing
2017
FUNDING SOURCES
PARNASA 61 – Biomedical Fund

15. An Israeli company managed by Parnasa Nihul Basad Ltd, seeking to raise $1.715
million in equity capitalization.
The Company’s investment objective is to generate superior long-term capital
appreciation through private equity investments in early-stage private companies
primarily based in the United States and Israel.
The Investment Manager is controlled by Eliezer Gross who holds a controlling interest
of management shares of the Company. The Investment Manager will be responsible
for the Company’s investment strategy and the management of the Company. He will
perform all day-to-day investment and asset management functions for the Company,
subject to the supervision and direction of the Company’s Board of Directors.
The Company has been formed to make seed and early-stage investments in the
common stock and preferred stock of start-up technology ventures located in Israel.
2017
PARNASA 61 - Biomedical Fund
PARNASA 61 – Biomedical Fund

16. INVESTMENT STRATEGYThe Company intends to invest substantially all of the proceeds of the sale of Shares
offered in the existing portfolio.
In addition, the Company may invest (or reinvest proceeds of exited investments) in
one or more other start-up technology ventures from time to time subject to the
availability of resources.
The Company intends to have multiple closings, so that any money that comes in
could immediately be used by the Company even if it is below the total amount of
capital sought to be raised pursuant to the official offering.
2017
INVESTMENT STRATEGY
PARNASA 61 – Biomedical Fund

17. The Company’ s existence is perpetual and therefore
dissolution and/or distribution of all or part of the
Company’s assets are not expected at any
time in the future.
6000 shares = $10,625.
Fund will bear all costs and expenses.
The Company is being treated as a corporation under
the Israeli tax laws.
December 31
25%
FUND
LIFE(TERM):
MINIMUM
PURCHASE:
OFFERING &
ORGANISATION
EXPENSES:
TAXATION:
FISCAL YEAR
END:
CARRIED
INTEREST:
2017
FUND STRUCTURE
PARNASA 61 – Biomedical Fund

18. MANAGEMENT TEAM
2017
MANAGEMENT TEAM
PARNASA 61 – Biomedical Fund
Eliezer Gross,
Founder and Chairman
With over 30 years of experience launching business
ventures in Israel, the United States, and Europe. He was a
founding partner of the American GBM Group, and of the
largest retail chains in Israel. Active in dozens of startup
initiatives and companies worldwide, he knows the U.S
market inside and out and has been influential in developing
many new products.
His keen business acumen has led him through the doors of
dozens of leading companies – primarily from the Fortune
100 including: Johnson & Johnson Corporation, CBS Studios,
Goodyear Tires, et al.

19. MANAGEMENT TEAM
2017
MANAGEMENT TEAM
PARNASA 61 – Biomedical Fund
Cobi Bitton
CEO, Besadno Group
Mr. Bitton is an entrepreneur, organizational consultant, and
expert in business development and the study of entrepreneurial
business models. He holds a Bachelor's degree in Industrial and
Management, an MBA and is highly knowledgeable about
conventional industrial production, environmental issues, and
safety and security products.
He was one of the entrepreneurs and founders of the SEC (Safe
Evacuation Coalition) - an advocacy group formed by companies,
and dedicated to promoting advanced emergency means of
egress solutions in the global market.
He has been counseling businesses, entrepreneurs, startups and
corporations for the past 25 years, empowering clients in the
American, Eastern and Central European, Latin, Russian, and
East Asian markets, among other locations. Cobi serves as the
CEO of Israel - Greece Chamber of Commerce, voluntarily.

20. MANAGEMENT TEAM
2017
MANAGEMENT TEAM
PARNASA 61 – Biomedical Fund
Gabby Hasson
CEO, Bseed Investments
Gabby is the CEO and Co-Founder of Bseed Investments,
with over 25 years of proven experience in the Investment,
IT and cutting-edge technology space in navigating and
uncovering opportunities for excellent growth and
profitability.
Previously, Gabby held management, Investment, and
business development positions, at CB Alliance (VC), IBM,
and HP, as well as Mashik Consulting and CTI. He
specialized in uncovering and enhancing solutions for
Mobile Telecom, Banking, and Online Marketing. Gabby
gained vast experience with IBM's Global Technology Unit
(GTU), that focused on startups and innovations.

21. MANAGEMENT TEAM
2017
MANAGEMENT TEAM
PARNASA 61 – Biomedical Fund
Mr. Eliashiv (LLB) is the Head of Development in the
Besadno Group. Oded has vast experience in the
Israeli startup industry, having led numerous ventures
in leading companies including Excellence Capital
Group (Singapore), Excellence AgriTech Solutions
(Cambodia), Slyde, ElectroPep, Beyond Interactive and
Epos Technologies.
Using his extensive experience in the startup
ecosystem, Oded is now advising early-stage startups
and providing them with the mentoring and fundraising
assistance.Oded Eliashiv
Head of Development,
Besadno Group